CA2981191C - Compositions comprising pregnancy specific glycoproteins and methods of use thereof - Google Patents
Compositions comprising pregnancy specific glycoproteins and methods of use thereof Download PDFInfo
- Publication number
- CA2981191C CA2981191C CA2981191A CA2981191A CA2981191C CA 2981191 C CA2981191 C CA 2981191C CA 2981191 A CA2981191 A CA 2981191A CA 2981191 A CA2981191 A CA 2981191A CA 2981191 C CA2981191 C CA 2981191C
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- acid sequence
- seq
- peptide
- psg1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562219900P | 2015-09-17 | 2015-09-17 | |
| US62/219,900 | 2015-09-17 | ||
| PCT/US2016/052131 WO2017049082A2 (en) | 2015-09-17 | 2016-09-16 | Compositions comprising pregnancy specific glycoproteins and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2981191A1 CA2981191A1 (en) | 2017-03-23 |
| CA2981191C true CA2981191C (en) | 2022-09-13 |
Family
ID=58289625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2981191A Active CA2981191C (en) | 2015-09-17 | 2016-09-16 | Compositions comprising pregnancy specific glycoproteins and methods of use thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11007249B2 (enExample) |
| EP (1) | EP3261722B1 (enExample) |
| JP (1) | JP2018529625A (enExample) |
| AU (1) | AU2016323769B2 (enExample) |
| CA (1) | CA2981191C (enExample) |
| WO (1) | WO2017049082A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022219008A1 (en) | 2021-04-14 | 2022-10-20 | University College Cork - National University Of Ireland, Cork | Treatment of cerebrovascular events and neurological disorders |
| JP2024514194A (ja) | 2021-04-14 | 2024-03-28 | ユニバーシティ・カレッジ・コークーナショナル・ユニバーシティ・オブ・アイルランド，コーク | 変形性関節症の治療に使用するためのｐｓｇ１ |
| WO2024078729A1 (en) | 2022-10-14 | 2024-04-18 | University College Cork - National University Of Ireland, Cork | Placenta expressed proteins for use in the treatment of tendon injury |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5169835A (en) | 1989-01-18 | 1992-12-08 | Oklahoma Medical Research Foundation | Pregancy specific proteins applications |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| EP1578366A4 (en) * | 2002-10-09 | 2007-12-19 | Tolerrx Inc | MOLECULES PREFERABLY ASSOCIATED WITH EFFECTOR T CELLS OR REGULATORY T CELLS AND METHODS OF USE THEREOF |
| US9005616B2 (en) | 2009-08-31 | 2015-04-14 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
-
2016
- 2016-09-16 AU AU2016323769A patent/AU2016323769B2/en active Active
- 2016-09-16 JP JP2017551585A patent/JP2018529625A/ja active Pending
- 2016-09-16 US US15/561,622 patent/US11007249B2/en not_active Ceased
- 2016-09-16 EP EP16847381.7A patent/EP3261722B1/en active Active
- 2016-09-16 CA CA2981191A patent/CA2981191C/en active Active
- 2016-09-16 WO PCT/US2016/052131 patent/WO2017049082A2/en not_active Ceased
- 2016-09-16 US US18/319,314 patent/USRE50535E1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016323769A1 (en) | 2017-10-19 |
| US11007249B2 (en) | 2021-05-18 |
| EP3261722B1 (en) | 2021-04-14 |
| WO2017049082A3 (en) | 2017-05-04 |
| WO2017049082A2 (en) | 2017-03-23 |
| JP2018529625A (ja) | 2018-10-11 |
| CA2981191A1 (en) | 2017-03-23 |
| EP3261722A2 (en) | 2018-01-03 |
| USRE50535E1 (en) | 2025-08-19 |
| US20180177844A1 (en) | 2018-06-28 |
| AU2016323769B2 (en) | 2022-05-26 |
| EP3261722A4 (en) | 2018-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12060401B2 (en) | Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders | |
| KR102777151B1 (ko) | 인터루킨-2의 부분 효능제 | |
| KR102653758B1 (ko) | 인터류킨-2/인터류킨-2 수용체 알파 융합 단백질 및 사용 방법 | |
| CA2981191C (en) | Compositions comprising pregnancy specific glycoproteins and methods of use thereof | |
| JP2023106434A (ja) | 制御性ｔ細胞エピトープ | |
| EP1525221A1 (en) | Conjugate of notch signalling pathway modulators and their use in medical treatment | |
| CN114686429B (zh) | 一种激活nk细胞的肿瘤免疫治疗方法 | |
| AU2020368012A1 (en) | Compounds for immunomodulation | |
| KR20220044683A (ko) | 관절염 치료를 위한 hla-dr/cii 펩티드 복합체 | |
| KR20240007197A (ko) | 자가면역 및 동종면역 질환의 예방 및/또는 치료를 위한 면역억제성 항원-특이적 키메릭 항원 수용체 조절 t 세포 | |
| EP3191186B1 (en) | Compositions and methods of using interleukin-4 induced gene 1 (il4i1) | |
| US20210309707A1 (en) | Interferon-gamma biased agonists | |
| EP2931293B1 (en) | Compositions and methods for regulating erythropoiesis | |
| EP2032601B1 (en) | Peptides regulating the surface expression of the t cell receptor | |
| KR101739305B1 (ko) | 릴랙신을 유효성분으로 포함하는 항원 제시 세포의 성숙화 유도용 조성물 | |
| US20070041937A1 (en) | G-csf derivative for inducing immunological tolerance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210719 |
|
| EEER | Examination request |
Effective date: 20210719 |
|
| EEER | Examination request |
Effective date: 20210719 |